pet-imaging
(2)
RadioMedix and the cancer drugs that race the clock
A radioactive medicine has two jobs: find its target and arrive before its useful activity fades. RadioMedix has spent two decades working on both, from PET imaging to an investigational alpha therapy licensed to Sanofi.
Indi Molecular
Indi Molecular is a Culver City, California biotech developing a synthetic alternative to antibodies called Protein Catalyzed Capture (PCC) agents - small, stable cyclic peptides built with click chemistry that bind protein targets with antibody-like specificity while behaving like small-molecule drugs. Spun out of Caltech chemist James Heath's lab in 2013, the company applies its platform to targeted oncology therapeutics and PET imaging agents, aiming to reach targets long considered undruggable, including KRAS G12D pancreatic cancer and ovarian cancer.